Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.59)
# 244
Out of 5,150 analysts
28
Total ratings
65%
Success rate
30.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Initiates: Overweight | $40 | $27.37 | +46.15% | 1 | Mar 2, 2026 | |
| RLAY Relay Therapeutics | Maintains: Overweight | $13 → $15 | $9.70 | +54.64% | 3 | Feb 27, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $100 → $144 | $98.50 | +46.19% | 2 | Feb 26, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $50 → $53 | $45.41 | +16.71% | 4 | Feb 25, 2026 | |
| RCUS Arcus Biosciences | Downgrades: Equal-Weight | $30 → $23 | $21.65 | +6.24% | 5 | Feb 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $30 → $35 | $40.78 | -14.17% | 1 | Feb 11, 2026 | |
| ZYME Zymeworks | Upgrades: Overweight | $25 → $33 | $24.65 | +33.87% | 4 | Dec 12, 2025 | |
| BCAX Bicara Therapeutics | Maintains: Equal-Weight | $8 → $11 | $18.54 | -40.67% | 3 | Nov 11, 2025 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $60 | $31.65 | +89.57% | 1 | Oct 31, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $11.17 | +141.72% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $33.27 | +32.25% | 1 | Jun 26, 2025 |
Genmab
Mar 2, 2026
Initiates: Overweight
Price Target: $40
Current: $27.37
Upside: +46.15%
Relay Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $13 → $15
Current: $9.70
Upside: +54.64%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $100 → $144
Current: $98.50
Upside: +46.19%
Kiniksa Pharmaceuticals International,
Feb 25, 2026
Maintains: Overweight
Price Target: $50 → $53
Current: $45.41
Upside: +16.71%
Arcus Biosciences
Feb 12, 2026
Downgrades: Equal-Weight
Price Target: $30 → $23
Current: $21.65
Upside: +6.24%
Exelixis
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $30 → $35
Current: $40.78
Upside: -14.17%
Zymeworks
Dec 12, 2025
Upgrades: Overweight
Price Target: $25 → $33
Current: $24.65
Upside: +33.87%
Bicara Therapeutics
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $18.54
Upside: -40.67%
Immunocore Holdings
Oct 31, 2025
Initiates: Overweight
Price Target: $60
Current: $31.65
Upside: +89.57%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $11.17
Upside: +141.72%
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $33.27
Upside: +32.25%